

# Antimicrobial Prenylated Isoflavones from the Leaves of Amazonian Medicinal Plant *Vatairea guianensis* Aubl.

*Serhat S. Çiçek\*<sup>†</sup>, Mayra Galarza Pérez<sup>‡</sup>, Arlette Wenzel-Storjohann<sup>‡</sup>, Roberto M. Bezerra<sup>§</sup>, Jorge F. O. Segovia<sup>^</sup>, Ulrich Girreser<sup>#</sup>, Isamu Kanzaki<sup>||</sup> and Deniz Tasdemir<sup>‡,⊥</sup>*

<sup>†</sup> Department of Pharmaceutical Biology, Kiel University, Gutenbergstr. 76, 24118 Kiel, Germany

<sup>‡</sup> GEOMAR Centre for Marine Biotechnology (GEOMAR-Biotech), Research Unit Marine Natural Products Chemistry, GEOMAR Helmholtz Centre for Ocean Research Kiel, Am Kiel-Kanal 44, 24106 Kiel, Germany

<sup>§</sup> Laboratory of Bioprospection and Atomic Absorption, Federal University of Amapá, Rod. JK, Macapá, 68903-419 Amapá, Brazil

<sup>^</sup> Brazilian Agricultural Research Corporation, Ecoregional Research Unit, Rod. JK, Km 5, Macapá, 68903-419 Amapá, Brazil

<sup>#</sup> Department of Pharmaceutical and Medicinal Chemistry, Kiel University, Gutenbergstr. 76, 24118 Kiel, Germany

|| Laboratory of Bioprospection, University of Brasilia, Darcy Ribeiro Campus, 70910-900 Brasilia, DF,  
Brazil

⊥ Kiel University, Christian-Albrechts-Platz 4, 24118 Kiel, Germany

*This document is the Accepted Manuscript version of a Published Work that appeared in final form in  
The Journal of Natural Products, copyright © American Chemical Society after peer review and  
technical editing by the publisher. To access the final edited and published work see  
<https://doi.org/10.1021/acs.jnatprod.1c01035>.*






## ABSTRACT

*Vatairea guianensis* Aubl. (Fabaceae) is an Amazonian medicinal plant species traditionally used for treating skin diseases. In an initial screening, a *V. guianensis* leaf extract and its subextracts showed antibacterial and antifungal activities. The EtOAc subextract was selected for chemical work-up and afforded five known (**1–4**, and **8**) and six undescribed isoflavones, vatairenones C–H (**5–7**, **9–11**). All isoflavones are prenylated in position C-8, displaying either chain-prenylated (**1–7**) or ring-closed forms (**8–11**). The most bioactive compound **3** exhibited *in vitro* activity against clinically relevant bacteria and fungi with IC<sub>50</sub> values ranging from 6.8 to 26.9 μM. Due to its broad antimicrobial activity and low general toxicity compound **3** is a potential lead compound for structural modifications. The results of the present study support the ethnomedicinal use of *V. guianensis* in the treatment of dermatological disorders. <sup>1</sup>H NMR spectra of some of the isolated compounds showed intricate signal patterns, which might explain repeated errors in assigning the correct structure of the isoflavonoid B-ring in the literature and which we resolved by higher order spectra simulations.

*Vatairea guianensis* Aubl. (Fabaceae, Papilionoideae) is a common tree in the Brazilian Amazon region and its leaves and fruits are traditionally used for the treatment of dermatological mycosis.<sup>1-3</sup> The plant is commonly known as “fava de impingem”, “faveira amarela”, or “faveira grande do igapó” in Brazil.<sup>2</sup> Because of its floral morphology, the genus *Vatairea* was previously assigned to the Dalbergieae tribe, but was recently re-assigned to the unranked Vataireoid clade after DNA sequence based phylogenetic analyses.<sup>4,5</sup> Extensive pharmacological studies were performed on *Vatairea guianensis* lectin (VGL), which was obtained from its seeds and exhibited vasorelaxant and anti-inflammatory effects.<sup>1,6,7</sup>

Previous phytochemical investigations on the leaves of *V. guianensis* afforded prenylated isoflavones of the derrone- and lupiwighteone-type, such as vatairenones A and B.<sup>8-10</sup> A study by de Souza et al. revealed moderate antioxidant activity for three isolated isoflavones,<sup>8</sup> whereas another study confirmed the antifungal activity against *Candida dubliniensis* and *C. parapsilosis* of lupiwighteone (**1**) and 5,7,3'-trihydroxy-4'-methoxy-8-prenylisoflavone (**2**).<sup>9</sup> Da Silva et al. reported a cytotoxic effect of **1** against MCF-7 breast cancer cells, with an IC<sub>50</sub> of 4.7 μM.<sup>10</sup> Phytochemical investigations of the sapwood did not yield prenylated isoflavonoids, but the well-known isoflavone formononetin and the isoflavanol bolusanthol D.<sup>2</sup> In addition, the triterpenoids lupeol, α- and β-amyrin, germanicol, and betulinic acid were detected in the leaves of *V. guianensis*.<sup>8</sup>

As a part of our ongoing research on Amazonian medicinal plants,<sup>11,12</sup> we investigated the antimicrobial potential of *V. guianensis* leaf extract. Our main aim was to find bioactive natural products to rationally support the ethnomedicinal use of this species in the treatment of dermatological ailments. Initial studies showed antibacterial and antifungal activity for the crude MeOH extract and its subextracts. In the following, we report isolation, structure elucidation, and antimicrobial and cytotoxic effects of five known and six so far undescribed prenylated isoflavones from the EtOAc subextract of *V. guianensis* leaves.



## RESULTS AND DISCUSSION

The crude MeOH extract of *V. guianensis* leaves exhibited activity against MRSA, *Enterococcus faecium*, and *Cryptococcus neoformans*. Subsequent partitioning of the crude extract between H<sub>2</sub>O and organic solvents of increasing polarity afforded four subextracts, *n*-hexane, CH<sub>2</sub>Cl<sub>2</sub>, EtOAc, and *n*-BuOH. The *n*-hexane subextract and the remaining H<sub>2</sub>O layer were inactive, but all other subextracts demonstrated activity against MRSA (IC<sub>50</sub> values ranging from 4.7 to 13.5 μg/mL). HPLC analysis of the bioactive subextracts indicated a similar chemical composition with varying concentrations of polar and apolar constituents. The EtOAc fraction revealed the most balanced ratio of polar and apolar metabolites and was selected for further work-up. Repeated chromatographic separations yielded a series of C-8 prenylated isoflavones. Five of the eleven isolates (**1–4**, and **8**) were identified as known natural products, whereas the remaining isoflavones are previously undescribed. In analogy to recently reported isoflavones vatairenones A and B isolated from *V. guianensis* leaves,<sup>10</sup> we named the undescribed compounds vatairenones C–H (**5–7**, **9–11**).

Compounds **1–4** and **8** were identified as lupiwighteone (**1**), 5,7,4'-trihydroxy-3'-methoxy-8-prenylisoflavone (**2**), 5,7,3'-trihydroxy-4'-methoxy-8-prenylisoflavone (**3**), lupiwighteone hydrate (**4**) and erypogin K (**8**) by comparison of their MS and NMR spectra with literature data (Tables S1–S3).<sup>9,13–15</sup> Optical rotation measurements combined with chiral phase HPLC analysis suggested that the latter compound was obtained as a scalemic mixture with an enantiomeric excess of 64% of the (*R*)-isomer (Figure S105).<sup>16</sup> However, in the case of compound **3**, initial structural assignment by comparison with literature data afforded a rather unusual 3',5'-substitution of the B-ring. A fact, which we clarified by spectra simulations and which will be explained later on.

Compound **5** (vatairenone C) was isolated as a light yellow powder and its molecular formula was deduced as C<sub>20</sub>H<sub>20</sub>O<sub>7</sub> based on HRESIMS measurements and the sodium adduct ion of *m/z* 395.1113 (calcd 395.1107). Analysis of the NMR data (Tables 1 and 2) indicated 20 carbon resonances, corresponding to two methyl groups ( $\delta_C$  27.8), six methane groups ( $\delta_C$  153.2, 123.6, 120.3, 116.1, 114.9, and 99.6), ten quaternary carbons ( $\delta_C$  162.0, 160.0, 155.6, 145.4, 144.9, 124.1, 122.8, 107.8, 104.9, and 70.2), and one conjugated carbonyl carbon ( $\delta_C$  180.8). The singlet at  $\delta_H$  8.05 and the <sup>13</sup>C NMR signals at  $\delta_C$  153.2 (C-2), 122.8 (C-3), and 180.8 (C-4) were consistent with an isoflavone core structure.<sup>17</sup> The NMR data further showed the presence of a prenyl moiety attached to C-8 as indicated by HMBC correlations of CH<sub>2</sub>-1" ( $\delta_H$  2.79) to C-8 ( $\delta_C$  107.8), C-7 ( $\delta_C$  162.0), and C-9 ( $\delta_C$  155.6). The only proton of the A-ring was assigned to H-6 ( $\delta_H$  6.20) due to its HMBC correlations to C-5 ( $\delta_C$  160.0), C-7, C-9, and C-10 ( $\delta_C$  104.9). These spectroscopic data were similar to those of **4**, but suggested a different substitution pattern of the B-ring. The HRESIMS of **5** showed a molecular weight of plus 16 compared to **4** and indicated additional hydroxylation. The proton NMR spectrum, furthermore, showed the presence of two doublets,  $\delta_H$  7.02 (H-2', *J* 2.0) and  $\delta_H$  6.81 (H-5', *J* 8.3), which were coupling with H-6' ( $\delta_H$  6.85) and indicated an ABX spin system for the B-ring. Thus, **5** had to be 3',4'-*ortho*-substituted and the structure of **5** was established as 8-(3-hydroxy-3-methylbutyl)-5,7,3',4'-tetrahydroxyisoflavone.

**Table 1.**  $^1\text{H}$  NMR (400.33 MHz) Spectroscopic Data of Compounds **5**, **6**, **7**, **9**, and **11** in  $\text{MeOH-}d_4$  ( $\delta$  in ppm,  $J$  in Hz)

Position	<b>5</b>	<b>6</b>	<b>7</b>	<b>9</b>	<b>11</b>
2	8.05, s	8.18, s	8.10, s	8.11, s	8.17, s
6	6.20, s	6.28, s	6.25, s	6.27, s	6.20, s
2'	7.01, d (2.0)	7.17, d (1.9)	7.05, m <sup>a</sup>	7.15, br s	7.37, d (8.6)
3'					6.84, d (8.6)
5'	6.81, d (8.3)	6.86, d (8.2)	6.96, m <sup>a</sup>	6.84, d (8.1)	6.84, d (8.6)
6'	6.84, dd (8.3, 2.0)	6.98, dd (8.2, 1.9)	6.96, m <sup>a</sup>	6.96, d (8.1)	7.37, d (8.6)
	2.79, m	2.81, m	2.78, m	3.25, d (8.6)	2.72, dd (16.6, 5.4)
1''					3.04, dd (16.6, 5.4)
2''	1.68, m	1.69, m	1.67, m	4.83, t (8.6)	3.85, t (5.4)
4''	1.27, s	1.30, s	1.28, s	1.24, s	1.37, s
5''	1.27, s	1.30, s	1.28, s	1.30, s	1.33, s
OCH <sub>3</sub>		3.90, s	3.87, s	3.89, s	

<sup>a</sup> Higher order spin system (see discussion below).

Compound **6** (vatairenone D) was obtained as yellow powder. Its molecular formula was assigned as  $\text{C}_{21}\text{H}_{22}\text{O}_7$  based on HRESIMS and a sodium adduct ion of  $m/z$  409.1267 (calcd 409.1264). Both  $^1\text{H}$  and  $^{13}\text{C}$  NMR data (Tables 1 and 2) were similar to those of **5** except for the presence of a methoxy group ( $\delta_{\text{C}}$  56.4,  $\delta_{\text{H}}$  3.89), which was also indicated by the molecular weight of plus 14. HMBC correlations of the methoxy protons with C-3' suggested methoxylation in this position and the structure of the compound to be 8-(3-hydroxy-3-methylbutyl)-5,7,4'-trihydroxy-3'-methoxyisoflavone.

**Table 2.**  $^{13}\text{C}$  NMR (100.66 MHz) Spectroscopic Data of Compounds **5**, **6**, **7**, **9**, and **11** in  $\text{MeOH-}d_4$  ( $\delta$  in ppm)

Position	<b>5</b>	<b>6</b>	<b>7</b>	<b>9</b>	<b>11</b>
2	153.2, CH	155.4, CH	156.8, CH	153.3, CH	153.4, CH
3	122.8, C	124.3, C	124.0, C	122.8, C	124.9, C
4	180.8, C	180.3, C	182.4, C	180.2, C <sup>a</sup>	182.5, C
5	160.0, C	159.6, C	161.3, C	164.0, C <sup>a</sup>	160.5, C
6	99.6, CH	99.9, CH	99.8, CH	94.8, CH	100.6, CH
7	162.0, C	160.0, C	164.1, C	168.2, C	161.1, C
8	107.8, C	108.8, C	108.7, C	106.5, C	105.8, C
9	155.6, C	155.1, C	155.1, C	154.0, C	156.5, C
10	104.9, C	104.3, C	106.0, C	104.8, C	99.8, C
1'	124.1, C	123.0, C	125.3, C	122.9, C	124.8, C
2'	114.9, CH	114.1, CH	117.3, CH	113.7, CH	131.2, CH
3'	145.4, C	146.8, C	147.4, C	148.4, C <sup>a</sup>	116.3, CH
4'	144.9, C	147.9, C	149.2, C	149.0, C <sup>a</sup>	159.3, C
5'	116.1, CH	116.4, CH	112.5, CH	116.2, CH	116.3, CH
6'	120.3, CH	114.0, CH	121.6, CH	122.6, CH	131.2, CH
1''	17.1, CH <sub>2</sub>	18.4, CH <sub>2</sub>	18.4, CH <sub>2</sub>	27.3, CH <sub>2</sub>	25.7, CH <sub>2</sub>
2''	42.4, CH <sub>2</sub>	43.8, CH <sub>2</sub>	43.7, CH <sub>2</sub>	92.8, CH	69.1, CH
3''	70.2, C	71.6, C	71.5, C	71.9, C	79.7, C
4''	27.8, CH <sub>3</sub>	28.8, CH <sub>3</sub>	29.2, CH <sub>3</sub>	25.1, CH <sub>3</sub>	25.3, CH <sub>3</sub>
5''	27.8, CH <sub>3</sub>	30.0, CH <sub>3</sub>	29.2, CH <sub>3</sub>	24.9, CH <sub>3</sub>	21.2, CH <sub>3</sub>
OCH <sub>3</sub>		56.4, CH <sub>3</sub>	56.4, CH <sub>3</sub>	56.1, CH <sub>3</sub>	

<sup>a</sup>Chemical shift values obtained from HMBC correlations.



Compound **7** (vatairenone E) was obtained as light yellow powder and showed the same molecular formula ( $C_{21}H_{22}O_7$ ) as **6** based on HRESIMS measurements and the sodium adduct ion of  $m/z$  409.1267 (calcd 409.1264). Analysis of NMR data (Tables 1 and 2) revealed that **6** was another derivative of lupiwighteone hydrate (**4**) with a different substitution pattern in the B-ring. The presence of one hydroxy group and one methoxy group in the B-ring together with the higher order spin system also observed for compound **3** (see discussion below) indicated a 3'-hydroxy-4'-methoxy substitution pattern and the structure of **7** to be 8-(3-hydroxy-3-methylbutyl)-5,7,3'-trihydroxy-4'-methoxyisoflavone.

Compound **9** (vatairenone F) was obtained as light yellow powder and showed a sodium adduct ion of  $m/z$  407.1106 (calcd for 407.1107) in the HRESIMS spectrum corresponding to a molecular formula of  $C_{21}H_{20}O_7$ . Analysis of 1D and 2D NMR data (Tables 1 and 2) showed an isoflavone core structure with a hydroxyprenyl moiety in position C-8. However, compared to compounds **4–7**, the NMR signals of the 2" methylene group were moved downfield from values of  $\delta_C$  42–44 and  $\delta_H$  1.7, respectively, to values of  $\delta_C$  92.8 and  $\delta_H$  4.83, indicating a neighboring oxygen atom and thus ring-closed prenylation as present in erypogin K (**8**). The negative optical rotation ( $[\alpha]_D^{20}$  -5.67) suggested (*R*)-configuration of the compound or the respective enantiomer dominating in a scalemic mixture. The latter fact was confirmed by chiral phase HPLC analysis, where an excess of 68% of the (*R*)-enantiomer was determined (Figure S106). Moreover, the additional methoxy group as well as the coupling constants of the protons in the B-ring indicated a 4'-hydroxy-3'-methoxy substitution pattern as observed for **2** and **6**. Thus, the structure of **9** was established as 5,4'-dihydroxy-3'-methoxy-2"-hydroxyisopropylidihydrofurano[4,5:7,8]-isoflavone.

Compound **10** (vatairenone G) was obtained as light yellow powder and showed the same molecular formula ( $C_{21}H_{20}O_7$ ) as compound **9** according to a sodium adduct ion of  $m/z$  407.1106 (calcd for 407.1107) in the HRESIMS spectrum. Analysis of the NMR data (Table 3) showed a dihydrofurylic substructure resulting from ring-closed prenylation as observed for **8** and **9**. Thus, **10** had to be another erypogin K (**8**) derivative. Chiral phase HPLC analysis again revealed the presence of a scalemic mixture, with a ratio

of 3:1 for the two isomers (enantiomeric excess of 47%) (Figure S107). A negative optical rotation value suggested that also for **10** the (*R*)-isomer was dominating in the mixture. With regard to the substitution pattern of the B-ring, compound **10** showed the same characteristics as **3** and **7**, wherefore its structure was elucidated as 5,3'-dihydroxy-4'-methoxy-2''-hydroxyisopropylidihydrofurano[4,5:7,8]-isoflavone.

Compound **11** (vatairenone H) was obtained as light yellow powder and its molecular formula was deduced as C<sub>20</sub>H<sub>18</sub>O<sub>6</sub> due to a sodium adduct ion *m/z* 377.1009 (calcd 377.1001) in the HRESIMS spectrum. Thus, **11** showed the same molecular formula as erypogin K (**8**) as well as a negative optical rotation value ( $[\alpha]_{\text{D}}^{20}$  -12.33). Chiral phase HPLC analysis, furthermore, revealed that compound **11** appeared as a scalemic mixture with an enantiomeric excess of 45% of the major isomer (Figure S108). Circular dichroism studies on retamasin D, the flavone counterpart of **11**, discovered negative optical rotation for the (*R*)-isomer and thus confirmed the (*R*)-enantiomer dominating in our mixture.<sup>18</sup> Analysis of the NMR data (Tables 1 and 2) showed similar values for the B-ring as **8** but different shift values for the prenyl moiety. The lower shift value of the CH-2'' methine group ( $\delta_{\text{C}}$  69.1 and  $\delta_{\text{H}}$  3.85) and the higher shift value of C-3'' ( $\delta_{\text{C}}$  79.7) suggested that the latter carbon was connected to the oxygen atom and that **11** showed a dihydropyrane substructure instead. This was consistent with the NMR data of vatairenone A, which was isolated in a previous study and showed the same substructure.<sup>11</sup> Thus, **11** was elucidated as 5,4'-dihydroxy-2'',2''-dimethyl-3''-hydroxydihydropyrano[5,6:7,8]-isoflavone.

**Table 3.** <sup>1</sup>H (400.33 MHz) and <sup>13</sup>C (100.66 MHz) NMR data of compounds **10** and **11** in DMSO-*d*<sub>6</sub> ( $\delta$  in ppm, *J* in Hz)


Position	<sup>1</sup> H NMR	<sup>13</sup> C NMR	<sup>1</sup> H NMR	<sup>13</sup> C NMR
2	8.36, s	154.3, CH	8.16, s	154.5, CH
3		122.8, C		123.1, C

4		180.8, C		180.9, C
5		162.0, C		159.4, C
6	6.30, s	94.2, CH	6.25, s	99.6, CH
7		166.9, C		160.0, C
8		104.4, C		105.9, C
9		152.6, C		155.3, C
10		105.3, C		105.3, C
1'		123.9, C		121.4, C
2'	7.02, s <sup>a</sup>	115.6, CH	7.45, d (8.7)	130.7, CH
3'		146.7, C	6.88, d (8.7)	115.6, C
4'		148.2, C		158.2, C
5'	6.97, m <sup>a</sup>	112.4, CH	6.88, d (8.7)	115.6, CH
6'	6.94, m <sup>a</sup>	120.4, CH	7.45, d (8.7)	130.7, CH
	3.19, d (7.7)	26.6, CH <sub>2</sub>	2.66, dd (16.6, 6.7)	25.3, CH <sub>2</sub>
1''			2.98, dd (16.6, 5.1)	
2''	4.78, t (7.7)	92.0, CH	3.81, dd (6.5, 5.4)	67.2, CH
3''		70.5, C		79.4, C
4''	1.16, s	26.3, CH <sub>3</sub>	1.32, s	25.6, CH <sub>3</sub>
5''	1.17, s	25.3, CH <sub>3</sub>	1.37, s	21.6, CH <sub>3</sub>
OCH <sub>3</sub>	3.80, s	56.2, CH <sub>3</sub>		

---

<sup>a</sup> Higher order spin system (see discussion below).

As mentioned above, the tentative structural assignment of compound **3** (and consequently of **7** and **10**) by NMR spectroscopy and comparison with literature data afforded a prenylated isoflavone with an unusual 3',5'-hydroxylation pattern of ring B, one of the hydroxy groups being methylated (Fig. 1, top left). The measured  $^1\text{H}$  and  $^{13}\text{C}$  NMR shifts agreed well with reported values in the same NMR solvent.<sup>19</sup> The spin system of the three ring B protons is apparently rather simply formed by a doublet (integral 2 protons, H-2' and H-6') and a triplet (1 proton, H-4'), each signal split by about 1.1 Hz. In this analysis protons H-2' and H-6' have the same chemical shift. The simulated spectrum is displayed in Fig. 1 (top).



**Figure 1.** Expansion and enlargement of the aromatic region of the  $^1\text{H}$  NMR spectrum of compound **3** in  $\text{MeOH-}d_4$ , top: structure and simulated spectrum for a 1',3',5'-trisubstituted B ring, middle: measured spectrum, bottom: structure and-simulated higher order spectrum for a 1',3',4'-trisubstituted B ring.

An expansion of the aromatic region of the measured  $^1\text{H}$  NMR spectrum is shown in black (Fig. 1, middle). Two differences can be observed, the asymmetric multiplets, indicating higher order effects on signal intensities, and some additional side bands next to the main signal, indicating the outer lines of a higher order spin system. They display the AB part of an ABX system, with the two protons A and B having nearly the same chemical shift and presenting the protons 5' and 6' of a 1',3',4'-trisubstituted B ring (Fig. 1, bottom left). Simulation of the chemical shifts and coupling constants afforded the spectrum shown in blue color (Fig. 1, bottom). This spectrum showed the characteristics of the measured spectrum and delivered chemical shifts of 7.048 ppm for H-2' and a chemical shift difference of only 0.005 ppm between H-5' and H-6' (6.795 and 6.790 ppm, respectively). The coupling constants were in the expected range (8.4 and 2.0 Hz) and an additional coupling of 0.4 Hz for H-5' with H-2' was considered.

Chemical shift reasoning opposes a 1',3',5'-trisubstituted B ring structure as well. The value of the H-4' proton in *ortho*-position to two hydroxy groups would be expected to be low-frequency shifted by about 0.3 to 0.5 ppm compared to the protons H-2' and H-6'. Analysis of the  $^{13}\text{C}$  shift values corroborates the 3',4'-disubstitution of the B ring. In case of a 3',5'-dihydroxylated or dimethoxylated B ring, the carbon shifts are expected in the range of 155 to 160 ppm. With two substituents located at positions 3' and 4' the carbon shifts are in the range of 145 to 150 ppm and are only influenced to a small amount by methylation of the hydroxy substituents. The analysis of  $^1\text{H}$  and  $^{13}\text{C}$  chemical shifts in 3',5'-disubstituted B rings is supported by chemical shift values obtained from synthetically prepared isoflavonoids reported in the literature (Table S15).<sup>20-22</sup>

3',5'-dihydroxylated B-rings in isoflavanoids originating from plant biosynthesis are very unlikely and have been reported in the literature only about a dozen times with experimental NMR data.<sup>23-34</sup> Therefore, we carefully checked the reported data. The check considered (i) the employed NMR solvent and

frequency, (ii) if  $^1\text{H}$  or  $^{13}\text{C}$  chemical shifts reflect the symmetry of ring B in 3',5'-dihydroxy and 3',5'-dimethoxy derivatives, (iii)  $^1\text{H}$  chemical shifts of H-4' versus H-2' and H-6', and (iv)  $^{13}\text{C}$  chemical shifts of C-3' and C-5' as well as C-4', respectively (Table S16).

In almost all cases, the reported structures should be re-evaluated; only one publication convincingly proved the proposed 3',5'-substitution pattern of the B-ring.<sup>31</sup> Nonetheless, in many cases the higher order multiplet signals of a 3',4'-disubstituted isoflavonoid were recognized and assigned correctly.<sup>35,36</sup> Due to a completely different electronic interaction, this phenomenon is not observed in the corresponding flavonoid  $^1\text{H}$  NMR spectra. Here, H-6' in ring B is high frequency shifted, compared to H-5', and the resulting multiplets can be analyzed first order.<sup>37</sup>

Nine out of the eleven isolated compounds (**1–8**, and **10**) were analyzed for their *in vitro* antimicrobial and cytotoxic potential (Tables 4 and 5). Antibacterial assays were carried out against both Gram-positive (MRSA, *Enterococcus faecium*) and Gram-negative (*Acinetobacter baumannii*) bacteria. Antifungal activity was evaluated against *Candida albicans*, *Cryptococcus neoformans*, and the dermatophyte *Trichophyton rubrum*. In addition, cytotoxicity was assessed against three human cancer lines, melanoma (A-375), colon cancer (HCT-116) and human breast cancer (MB-231). General toxicity was assessed employing the non-cancerous human keratinocyte cell line (HaCaT). Cut-off values for both antimicrobial and cytotoxicity assays were defined with 100  $\mu\text{g/mL}$ , i.e.  $\text{IC}_{50}$  values were only determined for compounds with more than 50% inhibition at this concentration.

Only four compounds (**3**, **5–7**) exhibited activity against MRSA, with compound **3** being the most potent ( $\text{IC}_{50}$  value of 6.8  $\mu\text{M}$ ) (Table 4). Notably, all active compounds showed chain-open prenylation, while none of the compounds with ring-closed isoprene moieties were effective. Two compounds were active against *E. faecium*, with **3** again being the most effective compound ( $\text{IC}_{50}$  value 12.8  $\mu\text{M}$ ). In contrast, compound **6** showed only weak activity ( $\text{IC}_{50}$  value of 80.6  $\mu\text{M}$ ). A similar pattern was observed in the

antifungal assays against *C. albicans*, *C. neoformans*, and *T. rubrum*. Here, only **3** displayed activity with IC<sub>50</sub> values of 26.9, 13.6 and 12.2 μM, respectively. Thus, compound **3** showed activity against five out of the six tested microbial test strains. The fact that **3** was active against MRSA and *T. rubrum*, which both cause dermatological disorders, furthermore, corroborates the ethnomedicinal use of *V. guianensis* leaves.

**Table 4.** Antimicrobial effects of compounds **3** and **5–7**.

	MRSA	<i>E. faecium</i>	<i>C. albicans</i>	<i>C. neoformans</i>	<i>T. rubrum</i>
<b>3</b>	6.8 ± 0.3 ( <i>10.3</i> )	12.8 ± 1.1 ( <i>5.5</i> )	26.9 ± 2.7 ( <i>2.6</i> )	13.6 ± 2.7 ( <i>5.1</i> )	12.2 ± 0.3 ( <i>5.7</i> )
<b>5</b>	29.6 ± 0.8 (2.9) <sup>a</sup>	–	–	–	–
<b>6</b>	37.0 ± 1.3 (5.6) <sup>a</sup>	80.6 ± 2.3 (2.6) <sup>a</sup>	–	–	–
<b>7</b>	49.0 ± 3.4 (>5.5) <sup>a</sup>	–	–	–	–
<b>PC</b>	3.1 ± 0.3 <sup>a,b,c,d</sup>	0.6 ± 0.0 <sup>a,c</sup>	1.3 ± 0.1 <sup>a</sup>	0.2 ± 0.0 <sup>a</sup>	0.3 ± 0.0 <sup>a</sup>

The IC<sub>50</sub> values are in μM. Selectivity index is indicated in parenthesis and in italics. Positive controls (PC): chloramphenicol (MRSA), ampicillin (*E. faecium*), nystatin (*C. albicans*) amphotericin B (*C. neoformans*), clotrimazole (*T. rubrum*). Statistical significance was determined by one-way ANOVA.

<sup>a</sup>  $p < 0.01$  as compared with compound **3**.

<sup>b</sup>  $p < 0.01$  as compared with compound **5**.

<sup>c</sup>  $p < 0.01$  as compared with compound **6**.

<sup>d</sup>  $p < 0.01$  as compared with compound **7**.

For  $p < 0.05$  all results were statistically significant from each other.

Cytotoxic effects of the tested compounds were lower and less differentiated, with most of the tested compounds showing no or only weak effects against cancer cell lines (Table 5). Moderate activities were observed for **1–3** against human malignant melanoma (A-375) cells with IC<sub>50</sub> values of 88.5, 58.2, and 58.4 μM, respectively. Compounds **2** and **3** exhibited marginal activity towards MB-231 and HCT-116 cells with the same IC<sub>50</sub> value of 87.5 μM. Except for **1**, all compounds (**2**, **3** and **5**) showed significant toxicity against the non-cancerous human keratinocyte cell line (HaCaT). Notably, **3** displays a selectivity index (SI) of 10 against MRSA and an SI of 5 against *E. faecium*, *C. neoformans*, and *T. rubrum*, respectively.

**Table 5.** Cytotoxicity of compounds **1–6**.

	A-375	HCT-116	MB-231	HaCaT
<b>1</b>	88.5 ± 0.9 ( <i>1.8</i> )	187.0 ± 10.7 ( <i>0.9</i> )	–	159.8 ± 0.9
<b>2</b>	58.2 ± 0.5 ( <i>1.4</i> )	109.5 ± 3.8 ( <i>1.9</i> )	87.5 ± 1.6 ( <i>1.5</i> )	80.7 ± 1.4
<b>3</b>	58.4 ± 1.6 ( <i>1.2</i> )	87.5 ± 0.5 ( <i>0.8</i> )	109.8 ± 8.7 ( <i>0.6</i> )	69.8 ± 3.3
<b>4</b>	159.8 ± 5.6 ( <i>0.8</i> )	222.5 ± 16.6 ( <i>1.4</i> )	153.9 ± 11.5 ( <i>0.9</i> )	134.6 ± 3.1
<b>5</b>	–	–	–	85.9 ± 7.4
<b>6</b>	250.2 ± 2.8 ( <i>0.8</i> )	233.7 ± 5.4 ( <i>0.9</i> )	–	207.0 ± 3.6
<b>PC</b>	0.4 ± 0.0	49.5 ± 2.2	25.8 ± 0.4	50.0 ± 1.7

The IC<sub>50</sub> values are in μM. Selectivity index is indicated in parenthesis and italic font. Positive control (PC) was doxorubicin.

Isoflavonoids and especially prenylated isoflavonoids are known to exhibit various biological effects.<sup>38</sup> A previous study on the osteogenic activities of genistein and its derivatives found that diprenylation in



positions C-6 and C-8 increases the bone protective effects, which were more pronounced when prenylation occurred at C-8.<sup>39</sup> A screening for anti-tumor promoters towards Epstein-Barr-Virus activation, furthermore, showed that single or double prenylation increased the compounds' inhibitory activity.<sup>40</sup> Glabridin, one of the most investigated prenylated isoflavonoids, has been shown to induce apoptosis in leukemia cells.<sup>41</sup> A fact that was also found for (*S*)-erypoeigin K,<sup>16</sup> which was part of the scalemic erypoeigin K (**8**) mixture obtained in our study. With regard to the antibacterial activity of complex isoflavonoids, a study on the legume seedling extracts found the effect against *Listeria monocytogenes* and MRSA correlating with the total content of C-6 prenylated compounds rather than with compounds prenylated in in positions C-8 or C-3'.<sup>42</sup>

Our study showed that also C-8-prenylated isoflavonoids demonstrate notable antibacterial activity, not only against MRSA but also against other clinically relevant strains. With respect to the antifungal activity, Souza et al. reported pronounced activity for the EtOAc-soluble portion of the crude ethanolic extract of *V. guianensis* leaves against four *Candida* species.<sup>9</sup> However, two isolated major components (**1** and **3**) only affected two of the investigated *Candida* species and were not active against *C. albicans* and *C. krusei*. Compound **1** also exhibited no effect against *C. albicans* in our study, whereas **3** was significantly active.

In summary, the present study revealed a series of complex isoflavones, of which six compounds (**5–7**, **9–11**) were identified as previously undescribed natural products. One of the isolated constituents (**3**) exhibited inhibitory effects against two clinically relevant bacterial and three fungal strains. Its broad antimicrobial activity and relatively low cytotoxicity renders compound **3** a potential candidate for further optimization by a medicinal chemistry approach. With the activity against two strains that cause dermatological disorders, our study, furthermore, corroborates the ethnomedicinal use of *V. guianensis* for treating skin diseases. Because of the restricted occurrence of isoflavones in plant kingdom and the increasing use of prenylated flavonoids for the development of new therapeutic agents,<sup>43</sup> *V. guianensis*

presents a source of valuable natural products. Apart from our phytopharmacological findings, our study revealed deceptive coupling patterns in the proton NMR spectra observed for 3',4'-disubstituted isoflavonoids, which have been the reason for several erroneously reported structures and which we resolved by higher order spectra simulations.

## EXPERIMENTAL SECTION

**General Experimental Procedures.** Thin layer chromatography was performed with precoated TLC plates (Silica gel 60 F254 Merck, Germany) using either EtOAc–MeOH– H<sub>2</sub>O (10:1:1.5, TLC system 1), CH<sub>2</sub>Cl<sub>2</sub>–MeOH (10:1, TLC system 2) or CH<sub>2</sub>Cl<sub>2</sub>–MeOH (10:2, TLC system 3) as eluents and vanillin sulfuric acid as spraying reagent. Flash chromatography was carried out with a Büchi PrepChrom C-700 chromatograph using a FlashPure EcoFlex Silica Gel SL cartridge (100 g/135 mL, irregular 40–63 µm particle size, Büchi Labortechnik GmbH, Essen, Germany). Column chromatography was performed with Sephadex LH-20 (GE Healthcare AB, Uppsala, Sweden). Semi-preparative HPLC was accomplished using a Waters Alliance e2695 Separations Module with an Alliance 2998 Photodiode Array detector, and a WFC III fraction collector (Waters, Milford, MA, USA) using a Phenomenex Aqua C18 column (250 × 10 mm, 5 µm particle size, Phenomenex, Aschaffenburg, Germany). HPLC-UV analyses were performed on an Ultimate 3000 chromatograph equipped with a HPG-3400SD pump, connected to a WPS-3000SL autosampler, TCC-3000SD column heater, and a variable wavelength detector VWD-3400RS (Thermo Scientific, Waltham, MA, USA). UHPLC-DAD-MS analyses were carried out on a Shimadzu Nexera 2 liquid chromatograph connected to an LC-MS triple quadrupole mass spectrometer using electrospray ionization (Shimadzu, Kyoto, Japan). A Phenomenex Luna Omega C18 column (100 × 2.1 mm, 1.6 µm particle size, Phenomenex, Aschaffenburg, Germany) was employed for the analysis of extracts, fractions, and pure compounds. Chiral phase HPLC analysis was performed on a Lux Amylose-1 column (250 × 4.6 mm, 3 µm particle size, Phenomenex, Aschaffenburg, Germany). Melting

points were measured on a Stuart SMP30 melting point apparatus (Cole-Palmer, Staffordshire, United Kingdom) using glass melting point tubes. IR spectra were recorded on a Spectrum 100 FT-IR Spectrometer (PerkinElmer, Waltham, United States) using attenuated total reflection. All compounds were measured as solids except compounds **5**, **9**, and **11**, which were applied as methanolic solutions and measured as films. High-resolution MS spectra were recorded on a micrOTOF II-High-performance TOF-MS system equipped with an electrospray ionization source (Bruker, Billerica, MA, USA). Specific rotation of the compounds was measured on a Jasco P-2000 polarimeter (Jasco, Pfungstadt, Germany). 1D ( $^1\text{H}$ ,  $^{13}\text{C}$ ) and 2D (HSQC, HMBC, COSY, NOESY) NMR spectra were recorded on a Bruker Avance III 400 NMR spectrometer operating at 400 MHz for the proton channel and 100 MHz for the  $^{13}\text{C}$  channel with a 5 mm PABBO broad band probe with a z gradient unit at 298 K (Bruker BioSpin GmbH, Rheinstetten, Germany). Reference values were 2.09 ( $^1\text{H}$ ) and 205.87 ( $^{13}\text{C}$ ) for acetone, 2.50 ( $^1\text{H}$ ) and 39.51 ppm ( $^{13}\text{C}$ ) for dimethyl sulfoxide as well as 3.31 ( $^1\text{H}$ ) and 49.15 ppm ( $^{13}\text{C}$ ) for MeOH, respectively. Structure elucidation and spectra simulations were performed using the Topspin 3.6 software (Bruker Biospin GmbH, Rheinstetten, Germany). Conventional 5 mm NMR sample tubes were obtained from Rototec-Spintec GmbH, Griesheim, Germany.

**Chemical reagents.** LC-MS grade formic acid was purchased from Sigma Aldrich Co., St. Louis, MO, USA. LC-MS grade MeCN, isopropanol, *n*-hexane, and H<sub>2</sub>O, gradient grade MeOH, and other (analytical grade) solvents were obtained from VWR International GmbH, Darmstadt, Germany. H<sub>2</sub>O used for isolation was doubly distilled in-house. DMSO-*d*<sub>6</sub> (99.80%, Lot S1051, Batch 0119E) and MeOH-*d*<sub>4</sub> (99.80%, Lot P3021, Batch 1016B) for NMR spectroscopy were purchased from Euriso-top GmbH, Saarbrücken, Germany.

**Plant material.** Leaves of *V. guianensis* were collected in April 2020 at the coordinates N 00° 13'30.3"/W 051° 33'24.2", and identified by Jorge F.O. Segovia. A voucher specimen is kept in

EMBRAPA under the registration number BRM 027. The species was registered for access to the genetic heritage in SisGen with the process no. 00.038.174/0001-43.

**Extraction and isolation.** Dried and ground leaves (628.5 g) were extracted five times with 2 L of MeOH using ultra-sonication for 15 minutes followed by maceration for at least 12 hours to yield 137.9 g of crude extract after evaporation of the solvent. The crude MeOH extract was suspended in H<sub>2</sub>O and subsequently extracted with CH<sub>2</sub>Cl<sub>2</sub> and EtOAc giving 44.69 g of CH<sub>2</sub>Cl<sub>2</sub> subextract, 27.24 g of EtOAc subextract and 49.58 g of residue after evaporation of the aqueous layer.

For further separation, a portion (10.44 g) of the EtOAc subextract was subjected to flash chromatography using silica gel as stationary phase and a gradient going from 100% *n*-hexane to 100% EtOAc in 25 min and to 100% MeOH in another 25 min. Flow rate was set to 50 mL/min and 100 fractions of 25 mL were collected. Fractions were combined according to their similarity based on TLC analyses, affording a total of 10 fractions (A–J).

Fraction B (1.326 g) was further separated using Sephadex LH-20 chromatography (100 × 2.5 cm) and acetone as solvent to give 112 fractions, which were combined to 4 fractions (B1–B4) according to results of TLC system 2. Fraction B2 (vials 34–47, 439.2 mg) was subjected to the same column yielding 145 vials and, which were combined using TLC system 3 to yield five fractions (B2A–B2E). Fraction B2D (vials 73–90) consisted of 84.1 mg of **1** and fraction B2B yielded 6.90 mg of **2** and 21.4 mg of **3** after separation with semi-preparative HPLC using H<sub>2</sub>O–MeCN (50:50) as eluent and peak collection from 26.8 to 29.1 min and 29.2 to 33.0 min, respectively, at a temperature of 40°C.

Fraction E (781 mg) was also subjected to Sephadex LH-20 chromatography (100 × 2.5 cm, acetone) giving 228 vials, which were combined to 10 fractions (E1–E10) according to results of TLC system 3. Fraction E7 (vials 93–112, 43.9 mg) yielded 4.70 mg of **5** after purification by semi-preparative HPLC using H<sub>2</sub>O–MeCN (70:30 at 40°C) and peak collection from 18.4 to 23.0 min. Fraction E5 (141.1 mg) was chromatographed over Sephadex LH-20 material (170 × 2.5 cm, MeOH) to yield 60.5 mg of **4**.

Fraction E4 (90.2 mg) was subjected to semi-preparative HPLC applying H<sub>2</sub>O–MeCN (65:35) as eluent and a separation temperature of 40°C to give 5.10 mg of **6** (22.5 to 24.3 min) and 21.7 mg of **7** (24.4 to 27.4 min). Fraction E3 (67.6 mg) was chromatographed by semi-preparative HPLC using H<sub>2</sub>O–MeCN (60:40 at 40°C) and yielded 2.60 mg of **8** (22.5 to 24.3 min), 4.20 mg of compound **10** (26.6 to 28.0 min) and 4.71 mg of a mixture of compounds **9** and **11**. After NMR spectroscopy the mixture was separated by Sephadex LH-20 chromatography (100 × 1 cm, MeOH) using LC-MS for peak differentiation to give 1.26 mg of **9** and 1.88 mg of **11**.

*Lupiwighteone (1)*: Light yellow powder; mp 144 °C; LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (35:65)] λ<sub>max</sub> 224, 264 (Figure S1); HRESIMS (positive) *m/z* 339.1226 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>19</sub>O<sub>5</sub>, 339.1232) and 361.1043 [M + Na]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>18</sub>O<sub>5</sub>Na, 361.1052) (Figure S3); <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub> and DMSO-*d*<sub>6</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub> and DMSO-*d*<sub>6</sub>, 100 MHz) see Tables S1–S3, and Figures S4–S13, Supporting Information.

*5,7,4'-trihydroxy-3'-methoxy-8-prenylisoflavone (2)*: Light yellow powder; mp 156 °C; LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (35:65)] λ<sub>max</sub> 220, 265 (Figure S14); HRESIMS (positive) *m/z* 391.1161 [M + Na]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>20</sub>O<sub>6</sub>Na, 391.1158) (Figure S16); <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub>, 100 MHz) see Tables S1 and S3, and Figures S17–S21, Supporting Information.

*5,7,3'-trihydroxy-4'-methoxy-8-prenylisoflavone (3)*: Light yellow powder; mp 163 °C; LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (35:65)] λ<sub>max</sub> 224, 265 (Figure S22); HRESIMS (positive) *m/z* = 391.1162 [M + Na]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>20</sub>O<sub>6</sub>Na, 391.1158) (Figure S24); <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub> and DMSO-*d*<sub>6</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub> and DMSO-*d*<sub>6</sub>, 100 MHz) see Tables S1–S3, and Figures S25–S34, Supporting Information.

*Lupiwighteone hydrate (4)*: Yellow powder; mp 244 °C (degradation); LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (60:40)] λ<sub>max</sub> 264 (Figure S33); HRESIMS (positive) *m/z* = 357.1343 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>21</sub>O<sub>6</sub>, 357.1338) and 379.1167 [M + Na]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>20</sub>O<sub>6</sub>Na, 379.1158) (Figure S35); <sup>1</sup>H NMR

(MeOH-*d*<sub>4</sub> and DMSO-*d*<sub>6</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub> and DMSO-*d*<sub>6</sub>, 100 MHz) see Tables S1–S3, and Figures S36–S45, Supporting Information. Compound **4** was isolated as a still impure sample.

*Vatairenone C (5)*: Light yellow powder; mp 262 °C (degradation); LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (70:30)] λ<sub>max</sub> 231, 264 (Figure S46); HRESIMS (positive) *m/z* 395.1113 [M + Na]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>20</sub>O<sub>7</sub>Na, 395.1107) (Figure S48); <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub>, 100 MHz) see Tables 1 and 2, and Figures S49–S53, Supporting Information.

*Vatairenone D (6)*: Yellow powder; mp 256 °C (degradation); LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (60:40)] λ<sub>max</sub> 231, 264 (Figure S54); HRESIMS (positive) *m/z* 409.1267 [M + Na]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>22</sub>O<sub>7</sub>Na, 409.1264) (Figure S55); <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub>, 100 MHz) see Tables 1 and 2, and Figures S56–S61, Supporting Information. Compound **6** was obtained as a still impure sample.

*Vatairenone E (7)*: Light yellow powder; mp 238 °C (degradation); LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (60:40)] λ<sub>max</sub> 229, 265 (Figure S62); HRESIMS (positive) *m/z* 409.1267 [M + Na]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>22</sub>O<sub>7</sub>Na, 409.1264) (Figure S64); <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub>, 100 MHz) see Tables 1 and 2, and Figures S65–S69, Supporting Information.

*Erypogin K (8)*: Light yellow powder; mp 252 °C; [α]<sup>20</sup><sub>D</sub> -46.80 (c 0.3, MeOH); LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (60:40)] λ<sub>max</sub> 227, 264 (Figure S70); HRESIMS (positive) *m/z* 377.1005 [M + Na]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>18</sub>O<sub>6</sub>Na, 377.1001) (Figure S72); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 400 MHz) and <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 100 MHz) see Tables S1 and S2, and Figures S73–S78, Supporting Information.

*Vatairenone F (9)*: Light yellow powder; mp 218 °C; [α]<sup>20</sup><sub>D</sub> -5.67 (c 0.1, MeOH); LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (60:40)] λ<sub>max</sub> 263 (Figure S79); HRESIMS (positive) *m/z* 407.1106 [M + Na]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>20</sub>O<sub>7</sub>Na, 407.1107) (Figure S81); <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub>, 100 MHz) see Tables 1 and 2, and Figures S82–S87, Supporting Information.

*Vatairenone G (10)*: Light yellow powder; mp 239 °C;  $[\alpha]_D^{20}$  -26.73 (c 0.1, MeOH); LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (60:40)]  $\lambda_{\max}$  229, 265 (Figure S88); HRESIMS (positive)  $m/z$  407.1102 [M + Na]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>20</sub>O<sub>7</sub>Na, 407.1107) (Figure S90); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 400 MHz) and <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 100 MHz) see Tables 1 and 2, and Figures S91–S96, Supporting Information.

*Vatairenone H (11)*: Light yellow powder; mp 222 °C;  $[\alpha]_D^{20}$  -12.33 (c 0.1, MeOH); LC-UV [0.1% formic acid in H<sub>2</sub>O–MeCN (60:40)]  $\lambda_{\max}$  242, 264 (Figure S97); HRESIMS (positive)  $m/z$  377.1009 [M + Na]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>18</sub>O<sub>6</sub>Na, 377.1001) (Figure S98); <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub> and DMSO-*d*<sub>6</sub>, 400 MHz) and <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub> and DMSO-*d*<sub>6</sub>, 100 MHz) see Tables 1–3, and Figures S82–S87 and S100–S104, Supporting Information.

**Biological activity.** Antibacterial and antifungal activity testing of all samples were performed as described by Çiçek et al.<sup>12</sup> Cytotoxicity and anti-dermatophytic assays were conducted as described by Pfeifer Barbosa et al.<sup>11</sup> Selectivity indices were calculated using the results obtained from human keratinocyte cell line HaCaT. For compound **7**, which showed no activity against HaCaT cells, selectivity index was calculated using a concentration of 259 μM (corresponding to the cut-off value of 100 μg/mL).

## ASSOCIATED CONTENT

**Supporting Information.** <sup>1</sup>H and <sup>13</sup>C NMR data of **1–4**, and **8**; UV, IR, HRESIMS, 1D and 2D NMR spectra of **1–11**; chromatograms of chiral phase HPLC analysis. This material is available free of charge via the Internet at <http://pubs.acs.org>.”

## AUTHOR INFORMATION

### Corresponding Author

Serhat S. Çiçek – Department of Pharmaceutical Biology, Kiel University, 24118 Kiel, Germany; orcid.org/0000-0002-3038-8523; Phone +49 431 880 1077; Email: [scicek@pharmazie.uni-kiel.de](mailto:scicek@pharmazie.uni-kiel.de)

## **Authors**

Mayra Galarza Pérez – Department of Pharmaceutical Biology, Kiel University, 24118 Kiel, Germany; orcid.org/0000-0002-6858-6517

Arlette Wenzel-Storjohann – GEOMAR Centre for Marine Biotechnology (GEOMAR-Biotech), Research Unit Marine Natural Products Chemistry, GEOMAR Helmholtz Centre for Ocean Research Kiel, Am Kiel-Kanal 44, 24106 Kiel, Germany; orcid.org/0000-0002-8839-5873

Roberto M. Bezerra – Laboratory of Bioprospection and Atomic Absorption, Federal University of Amapá, Rod. JK, Macapá, Amapá, Brazil; orcid.org/0000-0002-1836-4246

Jorge F. O. Segovia – Brazilian Agricultural Research Corporation, Ecoregional Research Unit, Rod. JK, Km 5, Macapá, Amapá, Brazil; orcid.org/0000-0003-3177-0721

Ulrich Girreser – Department of Pharmaceutical and Medicinal Chemistry, Kiel University, 24118 Kiel, Germany; orcid.org/0000-0002-4535-3657

Isamu Kanzaki – Laboratory of Bioprospection, University of Brasilia, Darcy Ribeiro Campus, Brasilia, DF, Brazil; orcid.org/0000-0002-4388-7057

Deniz Tasdemir – GEOMAR Centre for Marine Biotechnology (GEOMAR-Biotech), Research Unit Marine Natural Products Chemistry, GEOMAR Helmholtz Centre for Ocean Research Kiel, Am Kiel-Kanal 44, 24106 Kiel, Germany; orcid.org/0000-0002-7841-6271

## **Notes**



The authors declare no competing financial interest.

#### ACKNOWLEDGMENT

The authors thank Claudia Welsch (GEOMAR-Biotech) for HRESIMS and optical rotation measurements, Prof. Christian Zidorn for proof reading and the Federal District Funding Agency/FAP DF, Brazil for partially funding the work.

#### REFERENCES

1. Silva, H. C.; Nagano, C. S.; Souza, L. A. G.; Nascimento, K. S.; Isídoro, R.; Delatorre, P.; Rocha, B. A. M.; Sampaio, A. H.; Assreuy, A. M. S.; Pires, A.F.; Damasceno, L. E. A.; Marques-Domingos, G. F. O.; Cavada, B. S. *Process Biochem.* **2012**, *47*, 2347–2355.
2. de Souza, R. F.; da Silva, J. K. R.; da Silva, G. A.; Arruda, A. C.; da Silva, M. N.; Arruda, M. S. P. *Rev. Virtual Quim.* **2015**, *7*, 1893–1906.
3. Oliveira, A. A.; Segovia, J. F. O.; Sousa, V. Y. K.; Mata, E. C. G.; Gonçalves, M. C. A.; Bezerra, R. M.; Junior, P. O. M.; Kanzaki, L. I. B. *SpringerPlus* **2013**, *2*, 371.
4. Cardoso, D.; de Queiroz, L. P.; de Lima, H. C.; Sukanuma, E.; van den Berg, C.; Lavin, M. *Am. J. Bot.* **2013**, *100*, 403–421.
5. Cardoso, D.; Pennington, R. T.; de Queiroz, L. P.; Boatwright, J. S.; van Wyk, B.-E.; Wojciechowski, M. F.; Lavin, M. S. *Afric. J. Bot.* **2013**, *89*, 58–75.

6. Marques, G. F. O.; Osterne, V. J. S.; Almeida, L. M.; Oliveira, M. V.; Brizeno, L. A. C.; Pinto-Junior, V.R.; Santiago, M. Q.; Neco, A. H. B.; Mota, M. R. L.; Souza, L. A. G.; Nascimento, K. S.; Pires, A. F.; Cavada, B. S.; Assreuy, A. M. S. *Biochimie* **2017**, *140*, 58–65.
7. Marques, G. F. O.; Pires, A. F.; Osterne, V. J. S.; Pinto-Junior, V. R.; Silva, I. B.; Martins, M. G. Q.; Oliveira, M. V.; Gomes, A. M.; de Souza, L. A. G.; Pavão, M. S. G.; Cavada, B. S.; Assreuy, A. M. S.; Nascimento, K. S. *J. Mol. Recognit.* **2021**, *34*, e2922.
8. de Souza, R. F.; Marinho, V. H. S.; da Silva, G. A.; Costa, L. M.; da Silva, J. K. R.; Bastos, G. N. T.; Arruda, A. C.; da Silva, M. N.; Arruda, M. S. P. *J. Braz. Chem. Soc.* **2013**, *24*, 1857–1863.
9. Souza, R. F.; da Silva, G. A.; Arruda, A. C.; da Silva, M. N.; Santos, A. S.; Grisolia, D. P. A.; Silva, M. B.; Salgado, C.; Arruda, M. S. P. *J. Braz. Chem. Soc.* **2017**, *28*, 1132–1136.
10. Da Silva, G. A.; de Souza, R. F.; Marinho, V. H.; Pinheiro, W. B.; Pinto, L. C.; Montenegro, R. C.; Arruda, A. C.; Silva, M. N.; Arruda, M. S. *Sci. Plena* **2020**, *16*, 117201.
11. Pfeifer Barbosa, A. L.; Wenzel-Storjohann, A.; Diomedes Barbosa, J.; Zidorn, C.; Peifer, C.; Tasdemir, D.; Çiçek, S. S. *J. Ethnopharmacol.* **2019**, *233*, 94–100.
12. Çiçek, S. S.; Wenzel-Storjohann, A.; Girreser, U.; Tasdemir, D. *Rev. Bras. Farmacogn.* **2020**, *30*, 18–27.
13. Ji, S.; Li, Z.; Song, W.; Wang, Y.; Liang, W.; Li, K.; Tang, S.; Wang, Q.; Qiao, X.; Zhou, D.; Yu, S.; Ye, M. *J. Nat. Prod.* **2016**, *79*, 281–292.
14. Hashidoko, Y.; Tahara, S.; Mizutani, J. *Agric. Biol. Chem.* **1986**, *50*, 1797–1807.
15. Dai, J.; Shen, D.; Yoshida, W. Y.; Parrish, S. M.; Williams, P. G. *Planta Med.* **2012**, *78*, 1357–1362.

16. Hikita, K.; Saigusa, S.; Takeuchi, Y.; Matsuyama, H.; Nagai, R.; Kato, K.; Murata, T.; Tanaka, H.; Wagh, Y.S.; Asao, N.; Kaneda, N. *Bioorg. Med. Chem.* **2020**, *28*, 115940.
17. Deyou, T.; Marco, M.; Heydenreich, M.; Pan, F.; Gruhonjic, A.; Fitzpatrick, P. A.; Koch, A.; Dereese, S.; Pelletier, J.; Rissanen, K.; Yenesew, A.; Erdélyi, M. *J. Nat. Prod.* **2017**, *80*, 2060–2066.
18. Nur-e-Alam, M.; Yousaf, M.; Parveen, I.; Hafizur, R. M.; Ghani, U.; Ahmed, S.; Hameed, A.; Threadgill, M. D.; Al-Rehaily, A. J.; *Org. Biomol. Chem.* **2019**, *17*, 1266–1276.
19. Tchize Ndejoung, B.; Le S.; Sattler, I.; Dahse, H.-M.; Kothe, E.; Hertweck, C. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6473–6476.
20. Klier, L.; Bresser, T.; Nigst, T. A.; Karaghiosoff, K.; Knochel, P. *J. Am. Chem. Soc.* **2012**, *134*, 13584–13587.
21. Lee, J. I. *Bull. Korean Chem. Soc.* **2016**, *37*, 1132–1135.
22. Mkrtchyan, S.; Iaroshenko, V.O. *Chem. Commun.* **2020**, *56*, 2606–2609.
23. Xuan, B.; Du, X.; Li, X.; Shen, Z. *Nat. Prod. Res.* **2016**, *30*, 1423–1430.
24. Vitor, R. F.; Mota-Filipe, W.; Teixeira, G.; Borges, C.; Rodrigues, A. I.; Teixeira, A.; Paulo, A. J. *Ethnopharm.* **2004**, *93*, 363–370.
25. Simões, M. A. M.; Pinto, D. C. G. A.; Neves, B. M. R.; Silva, A. M. S. *Molecules* **2020**, *25*, 812.
26. Yang, R.-Y.; Lan, Y.-S.; Huang, Z.-J.; Shao, C.-L.; Liang, H.; Chen, Z.-F.; Li, J. *Chem. Nat. Comp.* **2012**, *48*, 674–676.
27. Shrestha, S. P.; Narukawa, Y.; Takeda, T. *Chem. Pharm. Bull.* **2007**, *55*, 926–929.
28. Wang, G.-R., Tang, W.-Z.; Yao, Q.-Q.; Zhong, H.; Liu, Y.-J. *J. Nat. Med.* **2010**, *64*, 358–361.

29. Tianjin University of Science and Technology, Chinese Patent 106589019 A, 2016.
30. El-Latif, A. R. R.; Shabana, M. H.; El-Gandour, A. H.; Mansour, R. M.; Sharaf, M.; *Chem. Nat. Comp.* **2003**, *39*, 536–537.
31. Kovalev, V. N.; Zatylnikova, O. A.; Kovalev, S. V. *Chem. Nat. Comp.* **2013**, *49*, 34–35.
32. Shen, H.; Sun, J.; Zhao, P.; Tang, M.; Liu, Y.; Xia, P. *Chem. Nat. Compd.* **2014**, *50*, 621–623.
33. Tianjin University of Science and Technology, Chinese Patent 105646621A, 2016.
34. Scribuhom, T.; Thongsri, Y.; Yenjai, C. *Asian J. Chem.* **2020**, *32*, 1788–1792.
35. Chien-Min Chiang, C.-M.; Chang, Y.-J.; Wu, J.-Y.; Chang, T.-S. *Molecules* **2017**, *22*, 87.
36. Li, S.; Liu, C.; Zhang, Y.; Tsao, R. *Phytochem. Anal.* **2021**, *32*, 640–653.
37. Yamauchi, K.; Mitsunaga, T.; Itakura, Y.; Batubara, I. *Fitoterapia* **2015**, *104*, 69–74.
38. Botta, B.; Menendez, P.; Zappia, G.; de Lima, R. A.; Torge, R.; delle Monachea, G. *Curr. Med. Chem.* **2009**, *16*, 3414–3468.
39. Zhang, Y.; Li, X.-L.; Yao, X.-S.; Wong, M.-S. *Arch. Pharm. Res.* **2008**, *31*, 1534–1539.
40. Ito, C.; Itoigawa, M.; Tan, H.T.; Tokuda, H.; Yang Mou, X.; Mukainaka, T.; Ishikawa, T.; Nishino, H.; Furukawa, H. *Cancer Lett.* **2000**, *152*, 187–192.
41. Huang, H.-L.; Hsieh, M.-J.; Chien, M.H.; Chen, H.-Y.; Yang, S.-F.; Hsiao, P.-C. *PLOS One* **2014**, *9*, e98943.
42. Araya-Cloutier, C.; den Besten, H. M. W.; Aisyah, S.; Gruppen, H.; Vincken, J.-P. *Food Chem.* **2017**, *226*, 193–201.

43. Shi, S.; Li, J.; Zhao, X.; Liu, Q.; Song, S.-J. *Phytochemistry* **2021**, *191*, 112895.



*Vatairea guianensis* Aubl.

